Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Código QR

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly serious medical and health problems. As effecti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhuang Cui, Wei Zhou, Qinxue Chang, Tiantian Zhang, Hui Wang, Xiangda Meng, Yuanyuan Liu, Hua Yan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	age-related macular degeneration (AMD) diabetic macular edema (DME) pathological myopia (PM) ranibizumab conbercept cost-effectiveness Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/261a2c47fe5a46f2a62404c500b97150
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Clinical therapeutic effects of intravitreal injection of Conbercept for macular edema in different types of retinal vein occlusion
por: Peng-Yao Lin, et al.
Publicado: (2021)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong AH, et al.
Publicado: (2013)

EFFECT OF ANTI-VEGF THERAPY ON THE STRUCTURAL STATE OF THE RETINA IN DIABETIC MACULAR EDEMA
por: M. M. Bikbov, et al.
Publicado: (2016)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan H, et al.
Publicado: (2014)

Efficacy of anti-VEGF therapy combined with iontophoresis of Xueshuantong injection on retinal vein obstruction with macular edema
por: Zi-Yue Xiang, et al.
Publicado: (2021)

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
por: Amoaku W, et al.
Publicado: (2018)

Primary treatment of diabetic macular edema
por: Tushar M Ranchod, et al.
Publicado: (2009)

Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa B, et al.
Publicado: (2021)

Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up
por: Yan Lu, et al.
Publicado: (2021)

Update on corticosteroids for diabetic macular edema
por: Schwartz SG, et al.
Publicado: (2016)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
por: Tagami M, et al.
Publicado: (2017)

Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual outcomes and microaneurysm formation
por: Kawamura M, et al.
Publicado: (2018)

Assessment of Reinjection Numbers and Intervals for Diabetic Macular Edema Patients Who Received Dexamethasone Intravitreal Implants in Germany and Switzerland
por: Augustin AJ, et al.
Publicado: (2021)

Clinical-Decision Criteria to Identify Recurrent Diabetic Macular Edema Patients Suitable for Fluocinolone Acetonide Implant Therapy (ILUVIEN®) and Follow-Up Considerations/Recommendations
por: Adán A, et al.
Publicado: (2020)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)

Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017)

Prospective, Single-Center, Six-Month Study of Intravitreal Ranibizumab for Macular Edema with Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-Perfused Retinal Area
por: Lee SJ, et al.
Publicado: (2020)

Pseudophakic cystoid macular edema: update 2016
por: Grzybowski A, et al.
Publicado: (2016)

Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis
por: Cui C, et al.
Publicado: (2017)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis N, et al.
Publicado: (2016)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken E, et al.
Publicado: (2020)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
por: Karagiannis D, et al.
Publicado: (2017)

Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
por: Rodolfo Mastropasqua, et al.
Publicado: (2018)

Real-World Outcomes in Diabetic Macular Edema for the 0.2 μg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
por: Mushtaq B, et al.
Publicado: (2021)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti D, et al.
Publicado: (2021)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat D, et al.
Publicado: (2020)

Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019)

Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients
por: Filek R, et al.
Publicado: (2019)

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
por: Andrzej Grzybowski, et al.
Publicado: (2021)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki H, et al.
Publicado: (2017)

Photobiomodulation Therapy for Age-Related Macular Degeneration and Diabetic Retinopathy: A Review
por: Muste JC, et al.
Publicado: (2021)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
por: Michalska-Małecka K, et al.
Publicado: (2016)

Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study
por: Leys AM, et al.
Publicado: (2020)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

Effect of oral tranexamic acid on macular edema associated with retinal vein occlusion or diabetes
por: Takeyama M, et al.
Publicado: (2017)

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema
por: Alsaedi NG, et al.
Publicado: (2021)